Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
A French nested case-control analysis (n=2,562 cases matched to 45,184 controls) found use of glucagon-like peptide 1 receptor agonists for 1-3 years was associated with an increased risk of thyroid cancer (adjusted HR 1.58, 95% CI 1.27-1.95)
Key points:
A systematic review and meta-analysis found GLP-1 receptor agonist treatment was associated with an increased risk of overall thyroid cancer (OR 1.52, 95%CI 1.01-2.29) (2).
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.